Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Good results with cervical cancer vaccine in young girls

Drug company GlaxoSmithKline have had a good result with their new vaccine which was designed to prevent infection with the virus that causes cervical cancer.

19 Dec 2005

Two tests in a lifetime will halve cervical cancer numbers in poor countries

Most women in developed countries are regularly screened for cervical cancer, but this is often not the case in poorer countries.

20 Nov 2005

Warnings to be put on condoms

The U.S. Food and Drug Administration (FDA) is calling for warnings to be placed on condoms.

14 Nov 2005

Rapid screen-and-treat methods significantly reduce cervical cancer precursor lesions

A new study led by Columbia University Medical Center researchers demonstrates the safety and efficacy of two low-tech diagnostic tools to significantly reduce the prevalence of cervical cancer precursor lesions.

3 Nov 2005

"Screen and treat” cervical cancer programs effective in poorly resourced areas

According to a new study two "screen and treat" cervical cancer prevention programs developed for high-risk women in low-resource settings resulted in a lower prevalence of precancerous cervical lesions and cervical cancer, according to a study in the November 2 issue of JAMA: The Journal of the American Medical Association.

2 Nov 2005

Updated vaccine against cervical cancer provides longer sustainable response

Drug company GlaxoSmithKline says that it's updated vaccine against the human papillomavirus (HPV), has produced a stronger immune response, than the original formula of the vaccine.

2 Nov 2005

A promising new vaccine against a pre-cancerous cervical virus

Updated data from a study on a promising new vaccine against a pre-cancerous cervical virus shows superior efficacy in preventing cervical pre-cancers and non-invasive cervical cancer

1 Nov 2005

Pre-teens need vaccine against sexually transmitted virus

According to a poll of doctors in the U.S., most would be prepared to give 11- and 12-year-old patients a vaccine to prevent infection with a sexually transmitted virus.

31 Oct 2005

Cervical cancer vaccine shows promising results but smear tests still vital

Hopes of an end to routine smear testing have been raised by promising results achieved by a prototype cervical cancer vaccine.

16 Oct 2005

Third Wave Technologies files patent suits against Chiron and Bayer

The company last Friday filed suit against Digene Corp., seeking a court ruling supporting Third Wave's right to sell its human papilloma virus (HPV) products. Third Wave today also filed suit against Chiron Corp., Bayer Corp., and Bayer HealthCare LLC asking for a similar ruling about its right to sell its hepatitis C virus products.

11 Oct 2005

100% efficacy for cervical cancer vaccine

Final-stage clinical trials of a cervical cancer vaccine developed by University of Queensland (UQ) scientists, have shown the drug to be 100 per cent effective.

10 Oct 2005

Large tumors that block the sinuses can be removed endoscopically through the nose

The endoscopic approach worked well not only to remove large inverted papillomas in 18 patients ages 36 to 74 but also to watch for regrowth of the tumors that have a high recurrence rate and a small chance of becoming cancer. Patients were treated as outpatients and 56 percent remained disease-free at 29 months.

5 Oct 2005

Substance found in cotton plant could help treat psoriasis

A substance found in the cotton plant could help treat the common skin disease psoriasis, according to new research from the Pharmacy School at Sunderland University launched at the British Pharmaceutical Conference in Manchester.

28 Sep 2005

Helix receives approval to conduct a clinical trial of Topical Interferon Alpha-2b in Sweden

Helix BioPharma today announced that it has received approval from Sweden's drug regulatory authority, the Medical Products Agency (MPA), to conduct a Phase II clinical trial of Topical Interferon Alpha-2b in patients with ano-genital warts (condylomata acuminata), who are positive for infection with the human papilloma virus (HPV).

12 Sep 2005

Proportion of high-risk HPV infections preventable by vaccine may vary by region

Vaccines currently being developed against two types of virus that cause cervical cancer - HPV16 or HPV18 - may prevent a larger proportion of high-risk HPV infections in Europe than sub-Saharan Africa, suggests a study being published online by The Lancet.

16 Aug 2005

Human papillomavirus (HPV) genotyping can benefit clinical practice

A study published in the current issue of the Journal of the National Cancer Institute (JNCI) concludes that genotyping of specific high-risk types of the human papillomavirus (HPV), the cause of virtually all cases of cervical cancer, can benefit clinical practice by enabling more focused attention on women who are at highest risk, announced Digene Corporation.

26 Jul 2005

High rates of cervical cancer are indicators of larger problems in access to health care

The report also finds that cervical cancer mortality, which is higher in certain geographic areas and populations, is a marker for other health disparities.

21 Jul 2005

Stressgen granted U.S. patent providing coverage for the manufacture of HspE7

Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted US Patent Number 6,900,035, covering methods of manufacturing HspE7, the Company's lead product candidate for human papillomavirus (HPV)- related diseases and cancer.

13 Jul 2005

Why cervical precancers disappear in some women and not in others

New research sheds light on why cervical precancers disappear in some women and not in others. Scientists at the Johns Hopkins Kimmel Cancer Center report in the July 1 issue of Clinical Cancer Research that the reason many of these lesions persist is an unlikely mix of human papilloma virus (HPV) strain and a woman's individual immune system.

6 Jul 2005

Research sheds light on why cervical precancers disappear in some women and not in others

New research sheds light on why cervical precancers disappear in some women and not in others. Scientists say the reason many of these lesions persist is an unlikely mix of human papilloma virus (HPV) strain and a woman’s individual immune system.

4 Jul 2005